Roy Chemaly, MD
Infectious Disease · Houston, TXNPI 1609976521
Payments from drug & device makers
Across 379 payments — averaging $3283.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$699K
- Genentech, Inc.$174K
- Takeda Pharmaceuticals U.S.A., Inc.$92K
- Oxford Immunotec USA Inc$62K
- Janssen Research & Development, LLC$26K
- Ablynx NV$23K
- plus $167K from 18 others
What the payments were for
- Consulting fees$246,02936%
- Speaking & faculty fees$258,16738%
- Travel & lodging$176,98626%
- Food & beverage$4,0451%
- Education$9430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 239 | $699,452 |
| Genentech, Inc. | 5 | $174,454 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $92,164 |
| Oxford Immunotec USA Inc | 15 | $62,353 |
| Janssen Research & Development, LLC | 3 | $26,077 |
| Ablynx NV | 2 | $23,125 |
| Biotest AG | 3 | $22,823 |
| Modernatx, Inc. | 12 | $20,488 |
| ADMA Biomanufacturing LLC | 2 | $20,000 |
| F. Hoffmann-la Roche AG | 4 | $18,097 |
| Paratek Pharmaceuticals, Inc. | 5 | $14,610 |
| Shionogi Inc | 13 | $14,142 |
| Partner Therapeutics, Inc. | 4 | $10,073 |
| Invivyd Inc | 5 | $8,798 |
| Gilead | 9 | $7,488 |
| Pfizer | 6 | $6,000 |
| Pierre Fabre Pharmaceuticals, Inc. | 6 | $4,726 |
| Janssen Global Services, LLC | 2 | $4,320 |
| AbbVie | 5 | $3,465 |
| Astellas Pharma US Inc | 4 | $3,081 |
| AstraZeneca | 1 | $3,000 |
| Genmark Diagnostics, Inc. | 2 | $2,816 |
| Qiagen, LLC | 1 | $1,500 |
| Life Technologies Corporation | 1 | $1,400 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PREVYMIS$90,092
- LIVTENCITY$33,546
- Moderna Covid-19 Vaccine$20,190
- TSPOT TB TEST$17,907
- ZERBAXA$15,487
- RECARBRIO$15,487
- T-SPOT.TB8$14,560
- NUZYRA$14,529
- Fetroja$11,149
- Leukine$9,975
- PEMGARDA$8,746
- ABRYSVO$6,000
- Veklury$6,000
- ENFLONSIA$3,480
- S-217622$2,520
- CRESEMBA$1,581
How this compares
$1,244,452 in reported general payments places this provider in the 95th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Houston
- Eleftherios MylonakisHouston$6.4M
- Roberto ArduinoHouston$2.1M
- Issam RaadHouston$2M
- Joseph GatheHouston$1.9M
- Kevin GrimesHouston$1.9M
- Jennifer WhitakerHouston$1.5M
- Karen VigilHouston$1.4M
- David HuangHouston$884K
- Luis OstroskyHouston$731K
- Dimitrios KontoyiannisHouston$706K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.